Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Virus DiseasesRNA Virus InfectionsRespiratory Tract DiseasesRespiratory Tract Infections
Interventions
BIOLOGICAL

Low dose of H7 VLP vaccine + Alhydrogel

Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart

BIOLOGICAL

Med dose of H7 VLP vaccine + Alhydrogel

Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart

BIOLOGICAL

High dose of H7 VLP vaccine + Alhydrogel

High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart

BIOLOGICAL

High dose of H7 VLP vaccine

High dose of H7 VLP vaccine, 2 doses given 21 days apart

BIOLOGICAL

Placebo

Placebo, 2 doses given 21 days apart

Trial Locations (1)

R3E 3R2

Canadian Science Centre for Human and Animal Health, Winnipeg

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Health Sciences Centre, Winnipeg, Manitoba

OTHER

collaborator

Public Health Agency of Canada (PHAC)

OTHER_GOV

collaborator

Syneos Health

OTHER

lead

Medicago

INDUSTRY